Browsing category:

Anti-Inflammatory


On April 3, 2013 the FDA approved the new drug application carbinoxamine maleate, CAS number 3505-38-2, for the treatment of allergic rhinitis. Targeted for patients suffering from seasonal and perennial allergic rhinitis, the approval of carbinoxamine is a novel approach to allergy relief. Carbinoxamine is the first sustained-release histamine receptor blocking agent that is indicated[…]

Read More

On March 6, 2013 encouraging results from a study involving rheumatoid arthritis medications were published. This study, available in the March 6 issue of the Journal of the American Medical Association, reassured patients who are taking the newest medications. Results concluded from this particular study revealed that these drugs do not appear to raise the[…]

Read More

On January 15, 2013 Santarus, Inc. announced that the FDA had approved Budesonide, as the brand name Ulceris, for the induction of remission in patients with mild, moderate and active forms of ulcerative colitis. As an extended release tablet, this new indication approval of budesonide is a vital and novel therapeutic option for patients. Adult[…]

Read More

With the patent for Clobex (clobetasol propionate) facing an expiration of September 22, 2017, this prescription medication used to treat adults and children 12 years and older with psoriasis is sure to have generic development. Clobetasol propionate is available as a topical steroid spray, and it is effectual as it decreases inflammation and suppresses an[…]

Read More

As the most common inflammatory arthritis among men, gout is an inconsistent condition. Gout may remit for long periods, present as flare-ups for days or weeks, or be chronic for months or longer. The advent of Febuxostat CAS# 144060-53-7, has offered hope to patients with this debilitating form of arthritis. As an effectual treatment for[…]

Read More

As a prescription medication used to treat adults and children 12 years and older with psoriasis or other certain skin conditions that cause red, flaky, and itchy skin, Clobetasol propionate, CAS number 25122-56-7, is effective  and safe. Known as the brand name Olux, which is marketed by Stiefel Laboratories, clobetasol propionate has a patent expiration[…]

Read More

Ciprofloxacin Hydrochloride, known as the brand name antibiotic Proquin XR, is an effectual fluoroquinolone. Marketed by Depomed, the patent for Proquin XR is set to expire on September 19, 2016. It is projected to flourish as a generic antibiotic, due in part to its ease of use as a once daily 500 milligram dose. Another[…]

Read More

The National Psoriasis Foundation reports that 7.5 million Americans suffer from psoriasis. This staggering number only highlights the need for effective and safe medications to treat this frustrating, embarrassing and uncomfortable condition.  Betamethasone Valerate is known as Luxiq, which is marketed by Stiefel and GlaxoSmithKline. As an aerosol foam treatment for patients with scalp psoriasis,[…]

Read More

Olopatadine CAS# 113806-05-6 & Olopatadine Hydrochloride CAS# 140462-76-6, are also known as Patanol and Pataday, which are marketed by Alcon. With the patent for olopatadine due to expire on June 6, 2015, researchers are looking forward to offering generic options of this popular allergy remedy. Olopatadine is effectual as an ophthalmic solution in the form[…]

Read More

Loteprednol Etabonate, also known as Lotemax, is an anti-inflammatory corticosteroid eye solution. As a prescription eye drop, loteprednol etabonate, CAS number 82034-46-6, is used to treat a variety of inflammatory eye conditions. These conditions typically affect the anterior chamber of the eye and include allergic conjunctivitis, superficial punctate keratitis, acne rosacea, Iritis, herpes zoster keratitis,[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service